RxDoctor Payments Data

Ujwal Neravetla, MD

Hospitalist · Hattiesburg, MSNPI 1992882138

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $298 and has fallen 75.2% since, to $74 in 2025.

$1,138in general payments, 2019–2025

Across 57 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$236
  • Johnson & Johnson$187
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$178
  • Gilead$162
  • Boehringer Ingelheim$151
  • E.r. Squibb & Sons, L.L.C.$64
  • plus $159 from 4 others

What the payments were for

  • Food & beverage$1,138100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,138 in reported general payments places this provider in the 65th percentile of 102 hospitalist providers in Mississippi.

See all hospitalist providers in Mississippi

Medicare billing

Part B allowed, 2024
$112,697
Medicare patients
433
Services billed
1,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$63,123
JardianceEmpagliflozin14$11,656
EntrestoSacubitril/Valsartan12$10,490
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,005
FarxigaDapagliflozin Propanediol12$9,498
Sucralfate14$3,360
Albuterol Sulfate HfaAlbuterol Sulfate28$741
Pantoprazole Sodium107$589
Metoprolol Succinate55$495
Levetiracetam13$481
Furosemide144$305
Lactulose18$294
Potassium Chloride43$241
Duloxetine Hcl24$239
Cefdinir29$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$63,12397 claims
Boehringer IngelheimJardiance$151$11,65614 claims
AstraZenecaFarxiga$30$9,49812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 102 hospitalist providers in Mississippi.

Other hospitalist in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →